Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury.
Citicoline is approved in Europe and Japan for use in stroke, head trauma and other neurological disorders. It is presently being evaluated in phase II/III stroke trials in the United States. Exogenous administration of CDP-choline provides both choline and cytidine which access the brain and serve as substrates for the synthesis of phosphatidylcholine, a primary neuronal membrane component; the choline also enhances brain acetylcholine synthesis. Membrane repair and regeneration is necessary for recovery from stroke. Furthermore, citicoline may alleviate free fatty acid-induced toxicity which accompanies ischemic insult. Data from many pre-clinical and clinical trials support the hypothesis that citicoline may be a safe and effective treatment for stroke.
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D002462:Cell Membrane / Q000187:drug effects; D002986:Clinical Trials as Topic; D003566:Cytidine Diphosphate Choline / Q000627:therapeutic use*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006801:Humans; D008563:Membrane Lipids / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D014481:United States
D005230:Fatty Acids, Nonesterified; D008563:Membrane Lipids; D003566:Cytidine Diphosphate Choline